XIAOMI-W
01810
BABA-W
09988
TENCENT
00700
4
BYD COMPANY
01211
5
MEITUAN-W
03690
HK Stock MarketDetailed Quotes
06628 TRANSCENTA-B
- 1.710
- -0.110-6.04%
Not Open Feb 27 16:08 CST
742.00MMarket Cap-1.89P/E (TTM)
2.220High1.580Low3.28MVolume1.970Open1.820Pre Close6.15MTurnover0.76%Turnover RatioLossP/E (Static)433.92MShares2.49052wk High0.75P/B742.00MFloat Cap0.50052wk Low--Dividend TTM433.92MShs Float16.180Historical High--Dividend LFY35.17%Amplitude0.500Historical Low1.877Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
TRANSCENTA-B News
[Brokerage Focus] Softbank China gives a strong Buy rating to Chuangsheng Group (06628), indicating that its potential value is underestimated by the market.
Jinwu Financial News | Softbank China Research indicates that Chuangsheng Group (06628) has an experienced and comprehensive team, with Global clinical research and development capabilities in China and the USA. They employ a multi-regional development Global Strategy, utilizing proprietary antibody discovery platforms, integrated CMC capabilities, advanced translational science platforms, and HiCB manufacturing technology to advance innovations in drugs for various diseases, while also providing CDMO services to generate revenue. The company's core product Osemitamab (TST001) is a potentially best-in-class humanized antibody targeting Claudin18.2 (CLDN18.2).
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
On January 14, TRANSCENTA-B (06628) spent 0.0244 million Hong Kong dollars to repurchase 0.0405 million shares.
TRANSCENTA-B (06628) announced that on January 14, 2025, the company invested 0.0244 million Hong Kong dollars...
TRANSCENTA-B (06628.HK) repurchased 0.01 million shares on January 10.
Gelonghui January 10th丨TRANSCENTA-B (06628.HK) announced that on January 10th, it spent HKD 6,100 to repurchase 0.01 million shares.
TRANSCENTA-B (06628.HK) spent 0.06 million HKD to repurchase 0.1 million shares on January 9.
On January 9, Legend Holdings Group-B (06628.HK) announced that it spent 0.06 million Hong Kong dollars to repurchase 0.1 million shares.
TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.
Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.
TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares on December 31.
Gelonghui, on December 31, announced that TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares, with a repurchase price ranging from 0.59 to 0.63 HKD per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
TRANSCENTA-B (06628) announced the latest Business progress on its new LIV-1 ADCs for the antitumor effects in models of triple-negative breast cancer at the 2024 SABCS.
TRANSCENTA-B (06628) announced that the 2024 San Antonio Breast Cancer Symposium (SABCS)...
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Chuangsheng Group - B (06628.HK) repurchased 0.069 million shares on December 5th for 0.0497 million Hong Kong dollars.
On December 5th, Grayscale Group-B (06628.HK) announced that it spent 0.0497 million Hong Kong dollars to repurchase 0.069 million shares.
Chuangsheng Group-B (06628.HK) has seen the executive director, chairman and CEO Qian Xueming increase shareholding by 0.15 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on December 2, Glorious Resources (06628.HK) was acquired by executive director, chairman, and CEO Qian Xueming in the market on November 27-28, 2024, with an average price per share of HK$0.61-0.64, totaling 0.15 million shares, involving approximately HK$0.093 million. After the increase, Qian Xueming's latest shareholding number is 37.3505 million shares, and the shareholding ratio has risen from 8.52% to 8.56%.
On November 27, Chuangsheng Group-B (06628.HK) spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Gelonghui November 27丨Chuangsheng Group-B (06628.HK) announced that on November 27, it spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Chuangsheng Group - B (06628) spent approximately 0.0112 million Hong Kong dollars to repurchase 0.0145 million shares on November 21.
Chuangsheng Group-B (06628) announced that on November 21, 2024, approximately 0.0112 million Hong Kong dollars were spent to repurchase 1....
Chuangsheng Group - B (06628.HK) spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares on November 20th.
Gelonghui, November 20丨Chuangsheng Group-B (06628.HK) announced that on November 20, it spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares.
Chuang Sheng Group -B (06628.HK) spent 0.049 million Hong Kong dollars to repurchase 0.059 million shares on November 19th.
Gelonghui, November 19丨Chuangsheng Group-B (06628.HK) announced that on November 19, it spent 0.049 million HKD to repurchase 0.059 million shares, with a repurchase price of 0.83 HKD per share.
Chun Sheng Group-B (06628.HK): Announced at the ESMO 2024 Congress, the latest business progress of OSEMITAMAB (TST001) triplet therapy for the first-line treatment of inspiring efficacy data for gastric or gastroesophageal junction adenocarcinoma.
On September 19th, Changsheng Group-B (06628.HK) announced updated research data on the G-queue for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) using Osemitamab (TST001) in combination with Narulitinib and CAPOX. The data from this queue has consistently shown encouraging efficacy since its announcement at the ASCO 2024 conference. The study results showed that in patients with known levels of CLDN18.2 and PD-L1 expression, patients with high/medium expression of CLDN18.2 had a median progression-free survival (mPFS).
TRANSCENTA-B: 2024 INTERIM REPORT
On September 10th, Chong Sheng Group-B (06628.HK) spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
GlueNet September 10th, Creatilon Group-B (06628.HK) announced that on September 10th, it spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.